参考文献

[1] Chiò, Adriano, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: A critical review[J]. Amyotrophic Lateral Sclerosis, 2009, 10(5-6):310-323.

[2] Beghi E, Logroscino G, Adriano Chiò, et al. The epidemiology of ALS and the role of population-based registries[J]. biochim biophys acta, 2006, 1762(11-12):0-1157.

[3] Matthew C Kiernan, Steve Vucic, Benjamin C Cheah, et al. Amyotrophic lateral sclerosis.Lancet[J]. Lancet, 2011, 377(9769):942-955.

[4] Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis[J]. Nature Reviews Neuroscience, 2013, 14(4):248-264.

[5] Mandrioli J, Faglioni P, Nichelli P, et al. Amyotrophic lateral sclerosis: Prognostic indicators of survival[J]. Amyotrophic lateral sclerosis: official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 2007, 7(4):211-220.

[6] Ferguson T A, Elman L B. Clinical presentation and diagnosis of Amyotrophic Lateral Sclerosis[J]. Neurorehabilitation, 2007, 22(6):409-416.

[7] Diagnosis T E T F O, Sclerosis M O A L, Andersen P M, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force[J]. European Journal of Neurology, 2012, 19(3):360-375.

[8] Sabatelli M, Madia F, Conte A, et al. Natural history of young-adult amyotrophic lateral sclerosis[J]. Neurology, 2008, 71(12):876-881.

[9] 中华医学会神经病学分会肌电图与临床神经电生理学组，中华医学会神经病学分会神经肌肉病学组．中国肌萎缩侧索硬化诊断和治疗指南[J]．中华神经科杂志，2012，45（7）：531-533．

[10] Chen Lu, Liu Xiaolu, Tang Lu, Zhang Nan, Fan Dongsheng. Long-Term Use of Riluzole Could Improve the Prognosis of Sporadic Amyotrophic Lateral Sclerosis Patients: A Real-World Cohort Study in China.[J]. Frontiers in aging neuroscience, 2016, 8: 246.

[11] Vandoorne Tijs, De Bock Katrien, Van Den Bosch Ludo. Energy metabolism in ALS: an underappreciated opportunity?[J]. Acta neuropathologica, 2018, 135(4):489-509.

[12] Britton D, Karam C, Schindler J S. Swallowing and Secretion Management in Neuromuscular Disease[J]. Clinics in Chest Medicine, 2018, 39(2):449-457.

[13] Steyn F J, Ioannides Z A, Van Eijk R P A, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival[J]. Journal of Neurology Neurosurgery & Psychiatry, 2018:jnnp-2017-317887.

[14] Ng L, Khan F, Young C A, et al. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease[J]. Cochrane Database of Systematic Reviews. 2017;1:CD011776.

[15] Soriani M H, Desnuelle C.Care management in amyotrophic lateral sclerosis[J]. Revue Neurologique, 2017:173(5):288-299.(https://www.daowen.com)

[16] Franceschini A D C, Mouro L F. Dysarthria and dysphagia in Amyotrophic Lateral Sclerosis with spinal onset: A study of quality of life related to swallowing[J]. Neurorehabilitation, 2014, 36(1):127-134.

[17] Richard S. Bedlack, Nanette Joyce, Gregory T. Carter, et al. Complementary and Alternative Therapies in ALS[J]. Neurologic Clinics, 2015, 33(4):909.

[18] Dysphagia in amyotrophic lateral sclerosis: prevalence and clinical findings[J]. Acta Neurologica Scandinavica, 2013, 128(6):397-401.

[19] Diagnosis T E T F O, Sclerosis M O A L, Andersen P M, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force[J]. European Journal of Neurology, 2012, 19(3):360-375.

[20] Miller R G, Jackson C E, Kasarskis E J, et al. Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology[J]. Neurology, 2009, 73(15):1218-1226.

[21] Rosenfeld J, Ellis A. Nutrition and Dietary Supplements in Motor Neuron Disease[J].Physical Medicine & Rehabilitation Clinics of North America, 2008, 19(3):573-589.

[22] 宿英英，潘速跃，高亮等．神经系统疾病经皮内镜下胃造口喂养中国专家共识[J]．肠外与肠内营养，2015，22（03）：129-132．

[23] 崔丽英，蒲传强，樊东升等．中国肌萎缩侧索硬化诊断和治疗指南[J]．中华神经科杂志，2012，45（07）：531-533．

[24] 宿英英，高岱佺，姬仲等．神经系统疾病肠内营养支持操作规范共识（2011版）[J]．中华神经科杂志，2011，44（11）：787-791．

[25] Chen L, Zhang B, Chen R, et al. Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry 2015, 86:1075-1081.

[26] https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm557102.htm

[27] Ahmed Rebekah M, Newcombe Rowena E A, Piper Amanda J, Lewis Simon J, Yee Brendon J, Kiernan Matthew C, Grunstein Ron R. Sleep disorders and respiratory function in amyotrophic lateral sclerosis.[J]. Sleep medicine reviews, 2016, 26: 33-42.

[28] Sancho J, Servera E, Morelot-Panzini C, et al. Non-invasive ventilation effectiveness and the effect of ventilatory mode on survival in ALS patients[J]. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 2014, 15(1-2):55-61.

[29] Nardi J, Prigent H, Adala A, et al. Nocturnal Oximetry and Transcutaneous Carbon Dioxide in Home-Ventilated Neuromuscular Patients[J]. Respiratory Care, 2012, 57(9):1425-1430.

[30] Baxter Susan K, Baird Wendy O, Thompson Sue, et al. The use of non-invasive ventilation at end of life in patients with motor neurone disease: a qualitative exploration of family carer and health professional experiences.. 2013, 27(6):516-523.